公开(公告)号：WO2018189379A1

公开(公告)日：2018-10-18

申请号：PCT/EP2018/059548

申请日：2018-04-13

Applicant: GAMAMABS PHARMA ,  INSTITUT CURIE

Inventor： BARRET, Jean-Marc ,  PROST, Jean-François ,  LAHMAR, Mehdi ,  DEGOVE, Stéphane ,  DUBREUIL, Olivier ,  NICOLAS, André ,  MESURE, Didier

IPC: C07K16/28 ,  G01N33/574

Abstract: The present invention relates to a human AMHRII-binding agent for its use for preventing or treating a cancer selected in a group of cancers comprising colon cancer, liver cancer, hepatocellular carcinoma, testis cancer, thyroid cancer, gastric cancer, gastrointestinal cancer, bladder cancer, pancreatic cancer, head and neck cancer, kidney cancer, liposarcoma, pleuramesothelioma, melanoma, sarcoma, brain cancer, osteocarcinoma and leukemia.

公开(公告)号：WO2016177664A1

公开(公告)日：2016-11-10

申请号：PCT/EP2016/059739

申请日：2016-05-02

Applicant: GAMAMABS PHARMA ,  INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM) ,  UNIVERSITE DE MONTPELLIER ,  INSTITUT REGIONAL DU CANCER DE MONTPELLIER

Inventor： CHARDÈS, Thierry ,  DUBREUIL, Olivier ,  PELEGRIN, André ,  LARBOURET, Christel ,  PROST, Jean-François ,  BARRET, Jean-Marc ,  DEGOVE, Stéphane

IPC: C07K16/32 ,  A61K39/395 ,  A61P35/00 ,  A61K39/00

CPC classification number: C07K16/2863 ,  A61K2039/505 ,  A61P35/00 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/73 ,  C07K2317/92

Abstract: The present disclosure relates to a neuregulin non competitive allosteric anti-human-HER3 antibody having a human constant region; and less than 65 % of the glycan structures carried by the glycosylation site of the antibody comprises a fucose molecule. The antibody is characterized by its variable sequences.

Abstract translation: 本公开涉及具有人恒定区的神经调节蛋白非竞争性变构抗人HER3抗体; 并且由抗体的糖基化位点携带的少于65％的聚糖结构包含岩藻糖分子。 抗体的特征在于其可变序列。

公开(公告)号：WO2021078959A1

公开(公告)日：2021-04-29

申请号：PCT/EP2020/079934

申请日：2020-10-23

Applicant: GAMAMABS PHARMA

Inventor： PROST, Jean-François ,  DUBREUIL, Olivier ,  BARRET, Jean-Marc ,  DEGOVE, Stéphane

IPC: A61P35/00 ,  A61P43/00 ,  C07K16/28

Abstract: The present invention relates to a competitive antagonist antibody that specifically binds to AMHR-II, said antibody comprising (a) a heavy chain wherein the variable domain comprises a H-CDR1 having a sequence set forth as SEQ ID NO: 3; a H-CDR2 having a sequence set forth as SEQ ID NO: 4; and a H-CDR3 having a sequence set forth as SEQ ID NO: 5; and (b) a light chain wherein the variable domain comprises at least a CDR selected from the group consisting of a L-CDR1 having a sequence set forth as SEQ ID NO: 8, a L-CDR2 having a sequence set forth as SEQ ID NO: 9; and a L-CDR3 having a sequence set forth as SEQ ID NO: 10. A nucleic acid sequence encoding said antibody, a vector comprising the nucleic acid sequence, a host cell comprising said nucleic acid sequence or vector, an immunoconjugate comprising the said antibody, a pharmaceutical composition comprising the said antibody or immunoconjugate, and the use as a drug of the said antibody, cell or composition is also considered in the present invention.

公开(公告)号：WO2017025458A1

公开(公告)日：2017-02-16

申请号：PCT/EP2016/068744

申请日：2016-08-05

Applicant: GAMAMABS PHARMA

Inventor： PROST, Jean-François ,  BARRET, Jean-Marc ,  DUBREUIL, Olivier ,  DESIGAUD, Delphine

IPC: A61K47/68 ,  C07K16/28 ,  G01N33/574 ,  A61P35/00

CPC classification number: A61K47/48561 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6869 ,  A61K51/1036 ,  A61K51/1093 ,  C07K16/2869 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/73 ,  C07K2317/77 ,  C07K2317/92 ,  G01N33/57415 ,  G01N33/57434 ,  G01N33/57442 ,  G01N33/57449 ,  G01N2333/72

Abstract: This invention relates to antibody drug conjugates (ADC), antibody conjugates (AC) and novel antibodies. Particularly, the ADC, AC and antibodies disclosed herein specifically bind to the human anti-Mullerian hormone type II receptor (AMHR-II) and can be used to treat and/or identify AMHR-II expressing cancers, such as prostate cancer, breast cancer and gynecologic cancers expressing AMHR-II, such as ovarian cancer, in particular metastatic ovarian cancer, serous cancer, hypernephroma, endometrioid, colloidal epithelium, prostate cancer, germ cell cancer, endometrial cancer, mixed Mullerian malignant tumor of the uterus, leiomyosarcoma, or endometrial stromal sarcoma.

Abstract translation: 本发明涉及抗体药物偶联物（ADC），抗体缀合物（AC）和新型抗体。 特别地，本文公开的ADC，AC和抗体特异性结合人抗Mullerian激素II型受体（AMHR-II），并且可用于治疗和/或鉴定表达AMHR-II的癌症，例如前列腺癌，乳腺癌 表达AMHR-II的妇科癌症，例如卵巢癌，特别是转移性卵巢癌，浆液性癌，超肾，子宫内膜样，胶质上皮，前列腺癌，生殖细胞癌，子宫内膜癌，子宫的混合穆勒氏恶性肿瘤，平滑肌肉瘤或 子宫内膜间质肉瘤

公开(公告)号：WO2021043849A1

公开(公告)日：2021-03-11

申请号：PCT/EP2020/074505

申请日：2020-09-02

Applicant: GAMAMABS PHARMA

Inventor： D'HOOGE, François ,  BARRET, Jean-Marc ,  PROST, Jean-François ,  DUBREUIL, Olivier ,  LAHMAR, Mehdi

IPC: C07K16/28 ,  A61K47/68 ,  A61K31/5517 ,  A61P35/00

Abstract: The present invention relates to an antibody drug conjugate (ADC) of general formula (I) (D-Lk1-C(O)-Lk2-C2H4-NH-Lk3)n-Ab. A pharmaceutical composition comprising, in a pharmaceutically acceptable medium, the said ADC is also concerned by the present invention, as well as the use of this ADC or composition as a medicament, and in particular in the prevention and/or the treatment of an anti-Müllerian hormone type II receptor (AMHRII) expressing cancer in an individual.

公开(公告)号：WO2018219956A1

公开(公告)日：2018-12-06

申请号：PCT/EP2018/064081

申请日：2018-05-29

Applicant: GAMAMABS PHARMA ,  INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM) ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  UNIVERSITE PARIS DESCARTES

Inventor： BARRET, Jean-Marc ,  PROST, Jean-François ,  LAHMAR, Mehdi ,  DEGOVE, Stéphane ,  BOUGHERARA, Houcine ,  DONNADIEU, Emmanuel

IPC: C07K16/28

Abstract: The present invention relates to a glyco-engineered Fc fragment-bearing compound for its use as an immunosuppression inhibitor in the treatment of a cancer-associated immunosuppression. The invention further relates to a pharmaceutical composition comprising at least this glyco-engineered Fc fragment-bearing compound.

公开(公告)号：WO2018189381A1

公开(公告)日：2018-10-18

申请号：PCT/EP2018/059553

申请日：2018-04-13

Applicant: GAMAMABS PHARMA ,  INSTITUT CURIE

Inventor： BARRET, Jean-Marc ,  PROST, Jean-François ,  LAHMAR, Mehdi ,  DEGOVE, Stéphane ,  DUBREUIL, Olivier ,  NICOLAS, André ,  MESURE, Didier

IPC: C07K16/28 ,  A61K31/337 ,  A61K31/7068 ,  A61K33/24 ,  G01N33/574 ,  A61P35/00

Abstract: The present invention relates to a human AMHRII-binding agent for its use for preventing or treating a lung cancer, and especially a non-small call lung cancer (NSCLC), and even more especially a NSCLC selected in a group comprising epidermoid NSCLC, adenocarcinoma NSCLC, large cells NSCLC and squamous cell carcinoma NSCLC and neuroendocrine NSCLC.